Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1207H vs Aflibercept in Neovascular Age-Related Macular Degeneration
NCT07489586Phase 3Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Mar 2026
- Primary completion
- Dec 2026
- Modality
- Fc-Fusion Proteins
01
Overview
Phase 3, randomised, double-blind trial of aflibercept in neovascular age-related macular degeneration (NVAMD) (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Best Corrected Visual Acuity at 12 weeks. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
aflibercept
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT07489586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07489586.